Abstract
Elevated low-density lipoprotein (LDL) and below normal high-density lipoprotein (HDL) cholesterol are risk factors for coronary heart disease (CHD). According to clinical guidelines, LDL cholesterol is the primary target for lipid-altering therapy. Many patients who develop CHD have LDL and HDL cholesterol levels that fall within the desirable or low-risk category; consequently, conventional measurements of plasma lipids may not accurately detect high-risk patients. This article discusses the clinical significance of lipoprotein subclasses and methods of measurement. Assessing lipoprotein subclasses provides a more comprehensive and efficacious therapeutic approach compared with the standard lipid profile.
| Original language | English |
|---|---|
| Pages (from-to) | 30, 32, 34, 37-41 |
| Journal | Nurse Practitioner |
| Volume | 26 |
| Issue number | 12 |
| DOIs | |
| State | Published - Dec 2001 |
Fingerprint
Dive into the research topics of 'Assessing Coronary Heart Disease Risk and Managing Lipids'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver